In March of this year, Wegovy was approved for overweight or obese patients with cardiovascular disease
This personalized strategy aims to ensure that every aspect of your plan is tailored to your unique genetic profile, enhancing your results and supporting long-term success
A 2026 clinical commentary in Functional Medicine noted that unstructured caloric restriction during GLP-1 therapy, particularly when it trends toward processed or nutrient-poor foods, can reduce the substrates needed to support beneficial bacteria like Bifidobacterium, Akkermansia muciniphila, and Lactobacillus species
In some ways, the failure of the first generation of PPAR agonists paved the way for the Ozempic revolution
Note: The low-current mode can charge large-capacity batteries, but the high-current gear cannot charge small-capacity batteries
The March 2026 announcement with Novo Nordisk matters because it shifts Hims & Hers' GLP 1 story from a compounded centric offering to broader access to FDA approved brands, layered on a weight loss membership priced from US$39 to US$149 a month